Detection and management of early stage inflammatory bowel disease: an update for clinicians

References

• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54.
   PubMed Web of Science ®Google Scholar
• Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res. 2016;14(2):111–119.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut. 2012;61(2):241–247.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Gower-Rousseau C. The IBD Disability Index should become a major secondary endpoint in clinical practice and in clinical trials. J Crohns Colitis. 2016;10(12):1375–1377.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with Inflammatory Bowel disease. Gastroenterology. 2017;152(2):351–361.
   PubMed Web of Science ®Google Scholar
• Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology. 2010;139(4):1147–1155.
   PubMed Web of Science ®Google Scholar
• Fiorino G, Morin M, Bonovas S, et al. Prevalence of bowel damage assessed by cross-sectional imaging in early Crohn’s disease and its impact on disease outcome. J Crohns Colitis. 2017;11(3):274–280.
   PubMed Web of Science ®Google Scholar
• Cosnes J, Bourrier A, Nion-Larmurier I, et al. Factors affecting outcomes in Crohn’s disease over 15 years. Gut. 2012;61(2):241–247.
   PubMedGoogle Scholar
• Magro F, Rodrigues A, Vieira AI, et al. Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. Inflamm Bowel Dis. 2012;18(3):573–583.
   PubMed Web of Science ®Google Scholar
• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770.
   PubMed Web of Science ®Google Scholar
• Roda G, Narula N, Pinotti R, et al. Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis. Aliment Pharmacol Ther. 2017;45(12):1481–1492.
   PubMed Web of Science ®Google Scholar
• Fumery M, Singh S, Dulai PS, et al. Natural history of adult ulcerative colitis in population-based Cohorts: a systematic review. Clin Gastroenterol Hepatol. 2018;16(3):343–356.
   PubMed Web of Science ®Google Scholar
• Torres J, Billioud V, Sachar DB, et al. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis. 2012;18(7):1356–1363.
   PubMed Web of Science ®Google Scholar
• Frolkis AD, Dykeman J, Negrón ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145:996–1006.
   PubMed Web of Science ®Google Scholar
• Pariente B, Cosnes J, Danese S, et al. Development of the Crohn’s disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011;17(6):1415–1422.
   PubMed Web of Science ®Google Scholar
• Choung RS, Princen F, Stockfisch TP, et al. Serologic microbial associated markers can predict Crohn’s disease behaviour years before disease diagnosis. Aliment Pharmacol Ther. 2016;43(12):1300–1310.
   PubMed Web of Science ®Google Scholar
• Van Schaik FD, Oldenburg B, Hart AR, et al. Serological markers predict inflammatory bowel disease years before the diagnosis. Gut. 2013;62(5):683–688.
   PubMed Web of Science ®Google Scholar
• Lochhead P, Khalili H, Ananthakrishnan AN, et al. Association between circulating levels of C-reactive protein and interleukin-6 and risk of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;14(6):818–824.
   PubMed Web of Science ®Google Scholar
• Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 2005;54(9):1232–1236.
   PubMed Web of Science ®Google Scholar
• Gremese E, Salaffi F, Bosello SL, et al. Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. Ann Rheum Dis. 2013;72(6):858–862.
   PubMed Web of Science ®Google Scholar
• Allen PB, Olivera P, Emery P, et al. Review article: moving towards common therapeutic goals in Crohn’s disease and rheumatoid arthritis. Aliment Pharmacol Ther. 2017;45(8):1058–1072.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2016;68(1):1–25.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Collaud BS, Boers M, et al. Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. Ann Rheum Dis. 2016;75(7):1268–1271.
   PubMed Web of Science ®Google Scholar
• Veny M, Esteller M, Ricart E, et al. Late Crohn’s disease patients present an increase in peripheral Th17 cells and cytokine production compared with early patients. Aliment Pharmacol Ther. 2010;31(5):561–572.
   PubMed Web of Science ®Google Scholar
• Rivera-Nieves J, Ho J, Bamias G, et al. Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis. Gastroenterology. 2006;131(5):1518–1529.
   PubMed Web of Science ®Google Scholar
• Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20:495–549.
   PubMed Web of Science ®Google Scholar
• Desreumaux P, Brandt E, Gambiez L, et al. Distinct cytokine patterns in early and chronic ileal lesions of Crohn’s disease. Gastroenterology. 1997;113(1):118–126.
   PubMed Web of Science ®Google Scholar
• Kugathasan S, Saubermann LJ, Smith L, et al. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut. 2007;56(12):1696–1705.
   PubMed Web of Science ®Google Scholar
• Kugathasan S, Denson LA, Walters TD, et al. Prediction of complicated disease course for children newly diagnosed with Crohn’s disease: a multicentre inception cohort study. Lancet. 2017;389(10080):1710–1718.
   PubMed Web of Science ®Google Scholar
• Verstockt S, Van der Goten J, Vancamelbeke M, et al. Molecular profiling of early Crohn‘s disease reveals a prominent role for WNT5A. ECCO. 2017;P067.
   Google Scholar
• Peyrin-Biroulet L, Billioud V, D’Haens G, et al. Development of the Paris definition of early Crohn’s disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol. 2012;107(12):1770–1776.
   PubMed Web of Science ®Google Scholar
• Pariente B, Mary JY, Danese S, et al. Development of the Lémann index to assess digestive tract damage in patients with Crohn’s disease. Gastroenterology. 2015;148(1):52–63.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis. 2010;16(1):15–22.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Peyrin-Biroulet L. Early intervention in Crohn’s disease: towards disease modification trials. Gut. 2017;66(12):2179–2187.
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Dehlavi MA, Fournier N, et al. Diagnostic delay in Crohn’s disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol. 2013;108(11):1744–1753.
   PubMed Web of Science ®Google Scholar
• Nahon S, Lahmek P, Paupard T, et al. Diagnostic delay is associated with a greater risk of early surgery in a French cohort of Crohn’s disease patients. Dig Dis Sci. 2016;61(11):3278–3284.
   PubMed Web of Science ®Google Scholar
• Pellino G, Sciaudone G, Selvaggi F, et al. Delayed diagnosis is influenced by the clinical pattern of Crohn’s disease and affects treatment outcomes and quality of life in the long term: a cross-sectional study of 361 patients in southern Italy. Eur J Gastroenterol Hepatol. 2015;27(2):175–181.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology. 2004;126(2):402–413.
   PubMed Web of Science ®Google Scholar
• Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine vs conventional management of Crohn’s disease: a randomized controlled trial. Gastroenterology. 2013;145(4):758–765.
   PubMed Web of Science ®Google Scholar
• Panes J, Lopez-Sanroman A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology. 2013;145(4):766–774.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Colombel J-F, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn’s disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010;105(7):1574–1582.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–1395.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Reinisch W, Mantzaris GJ, et al. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn’s disease—a SONIC post hoc analysis. Aliment Pharmacol Ther. 2015;41(8):734–746.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Rutgeerts PJ, Sandborn WJ, et al. Adalimumab induces deep remission in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12(3):414–422.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Reinisch W, Colombel JF, et al. Subgroup analysis of the placebocontrolled CHARM trial: increased remission rates through 3 years for adalimumab treated patients with early Crohn’s disease. J Crohns Colitis. 2013;7(3):213–221.
   PubMed Web of Science ®Google Scholar
• Khanna R, Bressler B, Levesque BG, et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomized controlled trial. Lancet. 2015;386(10006):1825–1834.
   PubMed Web of Science ®Google Scholar
• Safroneeva E, Vavricka SR, Fournier N, et al. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn’s disease. Aliment Pharmacol Ther. 2015;42(8):977–989.
   PubMed Web of Science ®Google Scholar
• Kwak MS, Kim DH, Park SJ, et al. Efficacy of early immunomodulator therapy on the outcomes of Crohn’s disease. BMC Gastroenterol. 2014;14:85.
   PubMed Web of Science ®Google Scholar
• Nuij V, Fuhler GM, Edel AJ, et al. Benefit of earlier anti-TNF treatment on IBD disease complications? J Crohns Colitis. 2015;9(11):997–1003.
   PubMed Web of Science ®Google Scholar
• Kim B, Cheon JH, Moon HJ, et al. Crohn’s disease prognosis and early immunomodulator therapy: results from the CONNECT study. J Gastroenterol Hepatol. 2016;31(1):126–312.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Chen BL, Mao R, et al. Early thiopurines versus conventional step-care therapy for modifying the disease course of early Crohn’s disease: a tertiary referral center cohort study. Medicine (Baltimore). 2015;94(31):e1148.
   PubMed Web of Science ®Google Scholar
• Nahon S, Lahmek P, Lesgourgues B, et al. Diagnostic delay in a French cohort of Crohn’s disease patients. J Crohns Colitis. 2014;8(9):964–969.
   PubMed Web of Science ®Google Scholar
• Maconi G, Orlandini L, Asthana AK, et al. The impact of symptoms, irritable bowel syndrome pattern and diagnostic investigations on the diagnostic delay of Crohn’s disease: a prospective study. Dig Liver Dis. 2015;47(8):646–651.
   PubMedGoogle Scholar
• Vavricka SR, Spigaglia SM, Rogler G, et al. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(3):496–505.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Mary JY, et al. Development of red flags index for early referral of adults with symptoms and signs suggestive of Crohn’s disease: an IOIBD initiative. J Crohns Colitis. 2015;9(8):601–606.
   PubMed Web of Science ®Google Scholar
• Ochsenkühn T, D’Haens G. Current misunderstandings in the management of ulcerative colitis. Gut. 2011;60(9):1294–1299.
   PubMed Web of Science ®Google Scholar
• Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400.
   PubMed Web of Science ®Google Scholar
• Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a Pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133(2):423–432.
   PubMed Web of Science ®Google Scholar
• Ledder O, Turner D. Seeing without looking: predicting mucosal healing without endoscopic evaluation in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2017;64(6):848–849.
   PubMed Web of Science ®Google Scholar
• Diedern K, Hoekman DR, Leek A, et al. Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission. Aliment Pharmacol Ther. 2017;45(7):951–960.
   PubMed Web of Science ®Google Scholar
• Lee HS, Park SH, Yang SK, et al. Long-term prognosis of ulcerative colitis and its temporal change between 1977 and 2013: a hospital-based cohort study from Korea. J Crohns Colitis. 2015;9(2):147–155.
   PubMed Web of Science ®Google Scholar
• Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13(4):481–489.
   PubMed Web of Science ®Google Scholar
• Jakobsen C, Jr BJ, Wewer V, et al. Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease: a population-based study. Aliment Pharmacol Ther. 2011;34(10):1217–1224.
   PubMed Web of Science ®Google Scholar
• Burisch J, Pedersen N, Cukovic-Cavka S. Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe: the ECCO-EpiCom Cohort. Inflamm Bowel Dis. 2014 Jan;20(1):36–46.
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55(1):47–53.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257–265.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2012;369(8):699–710.
   Web of Science ®Google Scholar
• Narula N, Peerani F, Meserve J, et al. Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium. Am J Gastroenterol. 2018;113(9):1345–1354.
   PubMed Web of Science ®Google Scholar
• Clamp SE, Myren J, Bouchier IA, et al. Diagnosis of inflammatory bowel disease: an international multicentre scoring system. Br Med J (Clin Res Ed). 1982;284(6309):91–95.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Loftus EV, Colombel JF, et al. The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol. 2012;105(2):289–297.
   Web of Science ®Google Scholar
• Lakatos PL, Golovics PA, David G, et al. Has there been a change in the natural history of Crohn’s disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977–2009. Am J Gastroenterol. 2012;107(4):579–588.
   PubMed Web of Science ®Google Scholar
• Vegh Z, Burisch J, Pedersen N, et al. Treatment steps, surgery, and hospitalization rates during the first year of follow-up in patients with inflammatory bowel diseases from the 2011 ECCO-epicom inception cohort. J Crohns Colitis. 2015;9(9):747–753.
   PubMed Web of Science ®Google Scholar
• Torres J, Caprioli F, Katsanos KH, et al. Predicting outcomes to optimize disease management in inflammatory bowel diseases. J Crohns Colitis. 2016;10(12):1385–1394.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338.
   PubMed Web of Science ®Google Scholar
• Panaccione R, Bossuyt P, Lukas M, et al. Superior endoscopic and deep remission outcomes in adults with moderate to severe Crohn’s disease managed with treat to target approach versus clinical symptoms: data from CALM. Digestive disease week; Chicago, IL; 2017
   Google Scholar
• Hoekman DR, Stibbe JA, Baert FJ, et al. Long-term outcome of early combined immunosuppression versus conventional management in newly diagnosed Crohn’s disease Daniël R Hoekman. J Crohns Colitis. 2018 Apr 27;12(5):517–524.
   PubMed Web of Science ®Google Scholar